TScan Therapeutics announced the Company will host a virtual key opinion leader, KOL, event to discuss updated results from its Phase 1 heme malignancies study and highlights from its oral presentation at the 2024 Tandem Meetings: Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy and the Center for International Blood and Marrow Transplant Research. The event will provide an in-depth review of the oral presentation related to TScan’s ongoing Phase 1 multi-arm clinical trial evaluating TSC-100 and TSC-101, which are designed to treat residual disease and prevent relapse following hematopoietic cell transplantation in patients with acute myeloid leukemia, myelodysplastic syndromes, or acute lymphocytic leukemia.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TCRX:
- TScan Therapeutics to Host Virtual KOL Event to Discuss Updated Results from Phase 1 Heme Malignancies Study Presented at the 2024 Tandem Meetings of ASTCT and CIBMTR
- TScan Therapeutics appoints Pinchasik as VP, Clinical Development
- TScan Therapeutics Expands Clinical Team with the Appointment of Dawn Pinchasik, M.D., M.S., as Vice President, Clinical Development
- TScan Therapeutics Welcomes Jason Amello as New CFO
- TScan Therapeutics Appoints Seasoned Industry Executive Jason A. Amello as Chief Financial Officer
